Claudia Mendoza-Pinto , Marcial Sánchez-Tecuatl , Roberto Berra-Romani , Iván Daniel Maya-Castro , Ivet Etchegaray-Morales , Pamela Munguía-Realpozo , Maura Cárdenas-García , Francisco Javier Arellano-Avendaño , Mario García-Carrasco
{"title":"机器学习在风湿性关节炎治疗反应预测中的应用:系统综述:抗MDA5抗体阳性皮肌炎患者的血清尿酸","authors":"Claudia Mendoza-Pinto , Marcial Sánchez-Tecuatl , Roberto Berra-Romani , Iván Daniel Maya-Castro , Ivet Etchegaray-Morales , Pamela Munguía-Realpozo , Maura Cárdenas-García , Francisco Javier Arellano-Avendaño , Mario García-Carrasco","doi":"10.1016/j.semarthrit.2024.152501","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to investigate the current status and performance of machine learning (ML) approaches in providing reproducible treatment response predictions.</p></div><div><h3>Methods</h3><p>This systematic review was conducted in accordance with the PRISMA statement and the CHARMS checklist. We searched PubMed, Cochrane Library, Web of Science, Scopus, and EBSCO databases for cohort studies that derived and/or validated ML models focused on predicting rheumatoid arthritis (RA) treatment response. We extracted data and critically appraised studies based on the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) and Prediction Model Risk of Bias Assessment Tool (PROBAST) guidelines.</p></div><div><h3>Results</h3><p>From 210 unduplicated records identified by the literature search, we retained 29 eligible studies. Of these studies, 10 developed a predictive model and reported a mean adherence to the TRIPOD guidelines of 45.6 % (95 % CI: 38.3–52.8 %). The remaining 19 studies not only developed a predictive model but also validated it externally, with a mean adherence of 42.9 % (95 % CI: 39.1–46.6 %). Most of the articles had an unclear risk of bias (41.4 %), followed by a high risk of bias, which was present in 37.9 %.</p></div><div><h3>Conclusions</h3><p>In recent years, ML methods have been increasingly used to predict treatment response in RA. Our critical appraisal revealed unclear and high risk of bias in most of the identified models, suggesting that researchers can do more to address the risk of bias and increase transparency, including the use of calibration measures and reporting methods for handling missing data.</p></div><div><h3>Funding</h3><p>None.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"68 ","pages":"Article 152501"},"PeriodicalIF":4.6000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049017224001410/pdfft?md5=8c5c0cc16bb161ec1cfa1a22e67d7aa7&pid=1-s2.0-S0049017224001410-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Machine learning in the prediction of treatment response in rheumatoid arthritis: A systematic review\",\"authors\":\"Claudia Mendoza-Pinto , Marcial Sánchez-Tecuatl , Roberto Berra-Romani , Iván Daniel Maya-Castro , Ivet Etchegaray-Morales , Pamela Munguía-Realpozo , Maura Cárdenas-García , Francisco Javier Arellano-Avendaño , Mario García-Carrasco\",\"doi\":\"10.1016/j.semarthrit.2024.152501\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>This study aimed to investigate the current status and performance of machine learning (ML) approaches in providing reproducible treatment response predictions.</p></div><div><h3>Methods</h3><p>This systematic review was conducted in accordance with the PRISMA statement and the CHARMS checklist. We searched PubMed, Cochrane Library, Web of Science, Scopus, and EBSCO databases for cohort studies that derived and/or validated ML models focused on predicting rheumatoid arthritis (RA) treatment response. We extracted data and critically appraised studies based on the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) and Prediction Model Risk of Bias Assessment Tool (PROBAST) guidelines.</p></div><div><h3>Results</h3><p>From 210 unduplicated records identified by the literature search, we retained 29 eligible studies. Of these studies, 10 developed a predictive model and reported a mean adherence to the TRIPOD guidelines of 45.6 % (95 % CI: 38.3–52.8 %). The remaining 19 studies not only developed a predictive model but also validated it externally, with a mean adherence of 42.9 % (95 % CI: 39.1–46.6 %). Most of the articles had an unclear risk of bias (41.4 %), followed by a high risk of bias, which was present in 37.9 %.</p></div><div><h3>Conclusions</h3><p>In recent years, ML methods have been increasingly used to predict treatment response in RA. Our critical appraisal revealed unclear and high risk of bias in most of the identified models, suggesting that researchers can do more to address the risk of bias and increase transparency, including the use of calibration measures and reporting methods for handling missing data.</p></div><div><h3>Funding</h3><p>None.</p></div>\",\"PeriodicalId\":21715,\"journal\":{\"name\":\"Seminars in arthritis and rheumatism\",\"volume\":\"68 \",\"pages\":\"Article 152501\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0049017224001410/pdfft?md5=8c5c0cc16bb161ec1cfa1a22e67d7aa7&pid=1-s2.0-S0049017224001410-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in arthritis and rheumatism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049017224001410\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017224001410","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Machine learning in the prediction of treatment response in rheumatoid arthritis: A systematic review
Objective
This study aimed to investigate the current status and performance of machine learning (ML) approaches in providing reproducible treatment response predictions.
Methods
This systematic review was conducted in accordance with the PRISMA statement and the CHARMS checklist. We searched PubMed, Cochrane Library, Web of Science, Scopus, and EBSCO databases for cohort studies that derived and/or validated ML models focused on predicting rheumatoid arthritis (RA) treatment response. We extracted data and critically appraised studies based on the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) and Prediction Model Risk of Bias Assessment Tool (PROBAST) guidelines.
Results
From 210 unduplicated records identified by the literature search, we retained 29 eligible studies. Of these studies, 10 developed a predictive model and reported a mean adherence to the TRIPOD guidelines of 45.6 % (95 % CI: 38.3–52.8 %). The remaining 19 studies not only developed a predictive model but also validated it externally, with a mean adherence of 42.9 % (95 % CI: 39.1–46.6 %). Most of the articles had an unclear risk of bias (41.4 %), followed by a high risk of bias, which was present in 37.9 %.
Conclusions
In recent years, ML methods have been increasingly used to predict treatment response in RA. Our critical appraisal revealed unclear and high risk of bias in most of the identified models, suggesting that researchers can do more to address the risk of bias and increase transparency, including the use of calibration measures and reporting methods for handling missing data.
期刊介绍:
Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.